Skip to main content

NEW YORK (

TheStreet

) --

CHANGE IN RATINGS

Bucyrus

(BUCY)

rated new Buy at Jefferies. $65 price target. Company should benefit from a reacceleration of the global mining cycle.

Joy Global

(JOYG)

rated new Neutral at Jefferies. Valuation call, based on a $63 price target.

McCormick

(MKC)

upgraded at Gabelli to Buy. Company is a market leader and will continue to see a lot of shelf space at WMT.

McCormick

(MKC)

price target higher at Barclays. MKC price target increased to $42 from $40 on surprisingly strong 2Q10 results, Barclays said. Maintain Equal Wright rating.

Scroll to Continue

TheStreet Recommends

Research in Motion

(RIMM)

price target plunged at Credit Suisse. RIMM price target slashed to $75 from $100. Volume acceleration coming, to offset pricing pressure. Maintain Outperform rating.

Research in Motion

(RIMM)

downgraded at Baird from Outperform to Neutral. $59 price target. Company is shipping fewer of its new products.

Questar

(STR)

upgraded at RBC from Sector Perform to Outperform. $59 price target. Company has attractive demographic growth.

Tupperware

(TUP)

upgraded at JP Morgan. Rating raised to Overweight from Neutral. Price target lowered to $57 from $58. 2010 EPS estimates lowered to $3.66 from $3.80.

STOCK COMMENTS / EPS CHANGES

Apple

(AAPL)

estimates, target boosted at Oppenheimer. Shares of AAPL now seen reaching $345. Estimates also upped, given expectations for a strong launch of the new iPhone. Outperform rating.

Autodesk

(ADSK)

estimates raised at Pacific Crest. ADSK estimates were increased through 2013. Company has yet to see a decline in Europe. Outperform rating and $40 price target.

AO Smith

(AOS)

estimates increased at Keybanc. AOS estimates were raised through 2011. Company is seeing better demand in motors and benefiting from a more favorable sales mix. Hold rating.

Dell

(DELL)

price target trimmed at Barclays by a dollar to $15 as margins still need improvement. Maintain Equal Weight rating.

Johnson & Johnson

(JNJ)

estimates cut at UBS through 2011. OTC facility in Washington will likely be closed longer than expected. Buy rating and $75 price target.

Merck

(MRK)

estimates upped at Citigroup. MRK estimates were boosted through 2015. Dulera was approved by the FDA and Daxas will likely be approved in the EU next quarter. Buy rating and $45 price target.

Noble

(NE)

estimates, target lowered at Citigroup. Estimates were cut through 2011. Company is seeing lower dayrates on one of its rigs. Buy rating and new $38 price target.

Oracle

(ORCL)

estimates increased at UBS through 2012. Company is seeing better license demand and realizing operating leverage. Buy rating and $31 price target.

Paychex

(PAYX)

estimates lowered at Goldman through 2012. Lower sales are weighing on margins. Sell rating and $26 price target.

Priceline.com

undefined

numbers cut at Citigroup. Shares of PCLN now seen reaching $250. Estimates also lowered, given the stronger dollar. Buy rating.

Tibco Software

(TIBX)

numbers raised at Goldman. Shares of TIBX now seen reaching $14. Estimates also increased, given better license revenue growth. Neutral rating.

This article was written by a staff member of TheStreet.com.